EXPLORE THE SCIENCE
TL;DR: A 2026 preprint in medRxiv warned that a standard Alzheimer’s disease biomarker-clock analysis can create a countdown paradox, where later biomarker-clock ages appear linked to faster mild cognitive impairment onset because of the way remaining time is…
Read article
TL;DR: A 2026 ADNI analysis posted to medRxiv found that brain-derived plasma pTau217 better predicted near-term amyloid positron emission tomography (PET) positivity than total plasma pTau217 in cognitively unimpaired amyloid-negative participants. Key Findin…
Read article
TL;DR: A 2026 preprint in medRxiv used amyloid positron-emission tomography, tau molecular imaging, and structural MRI to build individualized Alzheimer’s disease biomarker axes from ADNI and validate them in OASIS. Key Findings 12,430 ADNI images: The pipelin…
Read article
TL;DR: A 2026 Molecular Psychiatry study tested Regional Vulnerability Index for Alzheimer’s disease (RVI-AD), a structural-MRI score of how closely a person’s brain pattern resembles amyloid-positive Alzheimer’s disease, and found that higher RVI-AD predicted…
Read article
TL;DR: A 2026 medRxiv preprint tested SimulAD, an Alzheimer’s disease progression simulator, and reported that it reproduced mean amyloid-clearance results within 5% error across six major phase III anti-amyloid trials while also separating positive trials fro…
Read article